트리클라벤다졸 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the triclabendazole market size is projected to be USD 436 million in 2025, USD 452.70 million in 2026, and reach USD 560.40 million by 2031, growing at a CAGR of 4.36% from 2026 to 2031.

This report is Segmented by Application (Veterinary Livestock {Cattle, Sheep, and Goats}, and Human Health), by Product Type (Brand and Generic), by Distribution Channel (Veterinary Hospitals, Veterinary Clinics, and Pharmacies / Drug Stores), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (USD) for the Above Segments.

Global Triclabendazole Market Trends and Insights

Multi-Stage Efficacy Anchors Triclabendazole as Protocol Standard Despite Resistance Emergence

Triclabendazole is the only widely used flukicide that targets both immature and adult Fasciola species in standard treatment protocols when migrating juveniles drive acute hepatic pathology. It is established that the United States labeling for human fascioliasis and pharmacological characterization reinforces this multi-stage efficacy profile, which underpins continued veterinary reliance despite documented resistance signals. Results published in Frontiers in Veterinary Science showed high efficacy along with corresponding biochemical recovery patterns, supporting durability in targeted use frameworks. Australian producer-led programsconfirmed resistance across monitored dairy properties. Yet, producers maintained triclabendazole in seasonal strategies due to its unique immature fluke activity relative to alternatives, with reported gains in weaner growth when timing aligned to pre-winter juvenile peaks.

WHO Endorsement and FDA Validation Expand Commercial and Programmatic Access Channels

Egaten, the human triclabendazole product, is FDA approved for fascioliasis, which helped reduce ambiguity on safety and use in regulated settings and indirectly supported veterinary acceptance, where stewardship and pharmacovigilance data are valued. WHO-aligned donation programs for human fascioliasis cemented a global public health role that, in turn, lowered barriers for generics in veterinary markets as dossiers referenced safety and exposure insights from the human use experience. The downstream effect includes faster regulatory pathways in emerging markets where zoonotic disease control narratives influence ruminant drug policies, helping the triclabendazole market reach new prescriber bases through aligned public and private channels. In several jurisdictions across East Africa and Southeast Asia, validation from human programs catalyzed veterinary approvals and distribution infrastructure, improving product continuity and reducing stockouts that had hampered seasonal treatment planning. These access enablers complement evidence-based veterinary protocols and encourage formulary adoption that balances resistance stewardship with disease control goals.

Documented Triclabendazole Resistance Erodes First-Line Efficacy and Compels Protocol Adjustments

Resistance has been confirmed in multiple regions by 2026, shifting veterinary practice toward diagnostics-led dosing and more frequent rotation with alternate classes where immature efficacy tradeoffs are manageable. In Australia, structured producer programs recorded resistance across all monitored dairy farms in recent trials. However, the programs did not observe measurable production loss, a result that practitioners attribute to partial efficacy that still reduces acute disease risk relative to alternatives. Research in human fascioliasis indicated that host microbiome features were associated with treatment outcomes, showing that non-responders present distinct microbial signatures compared to responders, which complicates the attribution of all failures to parasite genetics alone. As per the data published by Farm Advisory Service in October 2024, resistance risk is elevated, veterinarians emphasize test-and-treat, coproantigen monitoring, and scheduled rotations that preserve efficacy for high-burden windows in the triclabendazole market. Sponsors fund resistance genotyping and coproantigen testing partnerships, but stewardship programs raise costs for smaller generic suppliers, tightening the economics for low-price entrants in competitive channels.

Other drivers and restraints analyzed in the detailed report include:

1. Climate Change Extends Transmission Seasons and Expands Snail Habitats into Previously Marginal Zones
2. Adoption of Fixed-Dose Combinations Enhances Compliance and Addresses Co-Infection Burdens
3. Stringent Residue Withdrawal Periods Restrict Treatment Timing and Limit Dairy Market Penetration

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Veterinary livestock accounted for 78.77% of the triclabendazole market share in 2025 and is projected to grow at a 5.34% CAGR through 2031, reflecting both climate-amplified exposure and stewardship-driven repeat interventions on confirmed cases. Demand concentrates in temperate and subtropical belts where poorly drained pastures, floodplains, and irrigated forage favor intermediate host snails that sustain transmission windows. North American cattle operations in wet bottomlands and Gulf Coast pastures maintain repeated seasonal treatments, while British Isles and northwest European herds respond to wetter summers and milder winters by compressing safe grazing intervals and advancing autumn treatments. Livestock segment durability rests on three reinforcing shifts in the triclabendazole market. Climate trends stretch exposure windows, which raises the number of herds entering seasonal treatment plans. Coproantigen ELISA and molecular diagnostics enable targeted interventions that substitute precision for blanket dosing, which improves clinical outcomes and drug stewardship at the cost of lower per-farm volumes. Together, these factors underpin the higher-than-market growth of the veterinary livestock segment in the triclabendazole market through 2031.

Geography Analysis

North America accounted for 41.34% of the triclabendazole market share in 2025, reflecting advanced veterinary infrastructure, widespread diagnostic adoption, and regulated distribution that favors clinically integrated prescribing. The United States leads regional volumes due to persistent fluke burdens in wet bottomlands and Gulf Coast pastures, which keeps biannual coverage common in risk-prone locales. Surveillance-led protocols deepen market resilience, with diagnostic-based confirmation guiding timing and rotation to manage resistance concerns in the triclabendazole market. Canada's growth aligns with integrated dairy health programs and cross-border regulatory alignment that eases product flow. In Mexico, rural access and price-sensitive segments favor generics, yet variable veterinary access slows uptake relative to the United States and Canada.

Asia Pacific is projected to register the fastest pace at an 8.32% CAGR, underpinned by climate-driven expansion of snail habitats and intensifying ruminant systems across diverse agro-ecologies. On the Qinghai-Tibet Plateau, modeling under plateau climatic conditions indicates expanded geographical suitability for fluke transmission into higher altitudes, which is already prompting proactive surveillance and response plans in yak and sheep ranges.

The market in Europe is driven by growth factors, while stewardship frameworks are constraining prophylactic dosing in dairy regions. Southern Europe's warming winters and variable rainfall patterns bring new pockets into regular treatment schedules, while Eastern European producers accelerate generic uptake from Indian and Chinese suppliers.

1. Elanco
2. Alivira Animal Health (SeQuent)
3. Bimeda
4. Chanelle Pharma
5. Hebei Veyong pharmaceutical Co., Ltd.
6. MSD Animal Health
7. Norbrook
8. Novartis
9. Virbac
10. Zoetis

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 High veterinary fascioliasis burden; only flukicide effective across all life stages
  • 4.2.2 WHO endorsement, donation-linked access, and FDA approval improve availability
  • 4.2.3 Multi-stage efficacy sustains protocol-standard status in flukicide programs
  • 4.2.4 Climate change expanding fascioliasis risk zones and seasonality
  • 4.2.5 Adoption of triclabendazole fixed-dose combinations (macrocyclic lactones, levamisole)
  • 4.2.6 Better diagnostics (coproantigen ELISA/molecular assays) enabling targeted treatment & surveillance
• 4.3 Market Restraints
  • 4.3.1 Growing triclabendazole resistance in Fasciola spp.
  • 4.3.2 Milk/meat residue withdrawal and lactation restrictions constrain dairy usage
  • 4.3.3 Stewardship/rotation protocols reduce prophylactic dosing frequency
  • 4.3.4 Human market monetization constrained by donation-based supply
• 4.4 Value-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Application
  • 5.1.1 Veterinary Livestock
    • 5.1.1.1 Cattle
    • 5.1.1.2 Sheep
    • 5.1.1.3 Goats
  • 5.1.2 Human Health
• 5.2 By Product Type
  • 5.2.1 Brand
  • 5.2.2 Generic
• 5.3 By Distribution Channel
  • 5.3.1 Veterinary Hospitals
  • 5.3.2 Veterinary Clinics
  • 5.3.3 Pharmacies / Drug Stores
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, Recent Developments)
  • 6.3.1 Elanco Animal Health
  • 6.3.2 Alivira Animal Health (SeQuent)
  • 6.3.3 Bimeda
  • 6.3.4 Chanelle Pharma
  • 6.3.5 Hebei Veyong pharmaceutical Co., Ltd.
  • 6.3.6 MSD Animal Health
  • 6.3.7 Norbrook
  • 6.3.8 Novartis AG
  • 6.3.9 Virbac
  • 6.3.10 Zoetis

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment